The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-11), Cocrystal Pharma's 9-Day RSI is 44.73.
The industry rank for Cocrystal Pharma's 9-Day RSI or its related term are showing as below:
FRA:8CC's 9-Day RSI is ranked better than 69.95% of 1421
companies
in the Biotechnology industry
Industry Median: 49.68
vs FRA:8CC: 44.73
Cocrystal Pharma (FRA:8CC) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cocrystal Pharma 9-Day RSI Related Terms
FRA:8CC vs HOOK, LNAI, CYCN: 9-Day RSI Comparison
For the Biotechnology subindustry, Cocrystal Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cocrystal Pharma (FRA:8CC) has a 9-Day RSI of 44.73 as of Jul. 11, 2026. According to the industry distribution chart, Cocrystal Pharma ranks #427 out of 1421 companies in the Biotechnology industry, placing it in the top 30%.
Is Cocrystal Pharma's 9-Day RSI too high?
Cocrystal Pharma's current 9-Day RSI is 44.73. The Biotechnology industry median 9-Day RSI is 49.68. Cocrystal Pharma's value of 44.73 is 10% below this industry median. Based on the distribution chart, Cocrystal Pharma ranks #427 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cocrystal Pharma has a GF Score™ of 17/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's 9-Day RSI compare to HOOK and LNAI?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #427 out of 1421 companies for 9-Day RSI. This puts Cocrystal Pharma in the upper half of its industry. The industry median 9-Day RSI is 49.68. Cocrystal Pharma's value of 44.73 is 10% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.68, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current 9-Day RSI of 44.73 is 10% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current 9-Day RSI is 44.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Cocrystal Pharma (FRA:8CC) is currently considered Possible Value Trap. The stock's GF Value™ is €2.43, compared to a current price of €0.86 — trading 64.8% below its estimated fair value. The current 9-Day RSI is 44.73 and 10% below the Biotechnology industry median of 49.68. Cocrystal Pharma's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cocrystal Pharma (FRA:8CC), the current 9-Day RSI is 44.73 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?
Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued.
The current stock price of €0.86 is trading 64.8% below its estimated GF Value™ of €2.43.
GuruFocus considers Cocrystal Pharma to be Possible Value Trap.
Key valuation signals for FRA:8CC:
9-Day RSI: 44.73
GF Value™: €2.43 vs. price of €0.86 (64.8% below fair value)
Industry Position: 10% below the Biotechnology median (#427 of 1421)
No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
17GF Score
Get the complete analysis for FRA:8CC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8CC has been successfully added to your 